Edward Bradley M.d.

Biography

Dr. Edward Bradley, also known as Ed, M.D., serves as Senior Vice President of Research & Development and Oncology Innovative Medicines Unit Head at MedImmune, LLC. As iMED head, Dr. Bradley leads the cross-functional teams responsible for the strategy, growth, and advancement of the oncology portfolio. Dr. Bradley joined MedImmune in August 2010, as Vice President, Clinical Development, Oncology. Dr. Bradley, a board-certified medical oncologist, earned his medical degree and completed his medical residencies at Harvard. He conducted his clinical oncology training in the Medicine Branch of the National Cancer Institute and was a fellow in Robert Gallo’s laboratory. He returned to the Harvard faculty as Director, Laboratory of Tumor Cell Biology in the Beth Israel- Brigham and Women’s Hospital, and has maintained a career-long involvement in immunologically focused therapies for cancer. As head of oncology for CETUS, he led the development and registration of interleukin-2 (ProLeukin) for renal cell carcinoma. He initiated and led Sterling Oncology and the Sterling-Winthrop Immunoconjugates Division, a subsidiary of Eastman-Kodak and initiated the US development of oxaliplatin (Eloxatin) following its acquisition by Sanofi. He has held other significant pharmaceutical development positions, including Head of Medical Sciences and Development for DuPont Pharmaceutical, Chief Medical Officer. USA, and global head of medical imaging development for Schering AG. Prior to joining MedImmune, Dr. Bradley was Vice President and Head, Oncology Development at Incyte and conducted the registration trials for ruxolitinib ( Jakafi.) Dr. Bradley has served as Chief Scientific Officer for an early-stage biotechnology company, has led successful clinical development programs in non-oncology areas, including efavirenz (Sustiva), tinzaparin (Innohep) and the US registration of clopidogrel (Plavix) and the imaging agent Definity. He has served on pharma sector scientific advisory boards, editorial review boards, and has authored over 50 peer-reviewed publications in the medical oncology area.

Research Interest

Oncology